Pharmaceutisch Weekblad

, Volume 10, Issue 6, pp 272–276 | Cite as

The influence of ofloxacin and enoxacin on the metabolic pathways of theophylline in healthy volunteers

A pilot study
  • W. J. A. Wijnands
  • T. J. Janssen
  • P. J. M. Guelen
  • T. B. Vree
  • T. M. C. de Witte
Original Articles


The pharmacokinetic parameters of theophylline and its major metabolites were measured in two healthy volunteers, after the administration of theophylline alone and during co-medication with ofloxacin, 200 mg twice daily, or enoxacin, 200 mg twice daily. During enoxacin co-medication, elimination half-lives of theophylline increased from 8.7 h to 17.4 h and from 6.1 h to 12.3 h, respectively. As the renal clearance of theophylline did not change, the decreased elimination of theophylline during enoxacin co-medication must result from a reduced metabolic clearance. Enoxacin co-medication caused a clearly decreased formation of the metabolitesI-methyluric acid and 3-methylxanthine, formed by N-demethylation, whereas the C-8 oxidation of theophylline was less influenced compared to the blank. Enoxacin's interference with the theophylline disposition is predominantly based on the inhibition of the microsomal N-demethylation. Ofloxacin co-medication did not induce a change in the plasma parameters or renal excretion of theophylline and its metabolites.


Drug interactions Enoxacin Metabolism Ofloxacin Pharmacokinetics Theophylline 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haley TJ. Metabolism and pharmacokinetics of theophylline in human neonates, children and adults. Drug Metab Rev 1983;14:295–335.PubMedGoogle Scholar
  2. 2.
    Hendeles L, Massanari M, Weinberg M. Theophylline. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetcs. Spokane: Applied Therapeutics Inc., 1986:1105–88.Google Scholar
  3. 3.
    Jonkman JHG, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:309–44.PubMedGoogle Scholar
  4. 4.
    Thomson RD, Nagasawa HT, Jenne JW. Determination of theophylline and its metabolites in human urine and serum by high-pressure liquid chromatography. J Lab Clin Med 1974;85:584–93.Google Scholar
  5. 5.
    Yesair DW, Branfman AR, Callahan MM. Human disposition and some biochemical aspects of methylxanthines. In: Spiller GA, ed. The methylxanthine beverages and foods: chemistry, consumption and health aspects. New York: Alan R. Liss Inc., 1984:215–33.Google Scholar
  6. 6.
    Wijnands WJA, Van Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984;2:108–9.Google Scholar
  7. 7.
    Wijnands WJA, Vree TB, Van Herwaarden CLA: Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol 1985;20:583–8.PubMedGoogle Scholar
  8. 8.
    Wijnands WJA, Vree TB, Van Herwaarden CLA. The influence of quinolone derivates on theophylline clearance. Br J Clin Pharmacol 1986;22:677–83.PubMedGoogle Scholar
  9. 9.
    Davies BI, Maesen FPV, Teengs JP. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother 1984;14(suppl C):83–9.PubMedGoogle Scholar
  10. 10.
    Raoof S, Wollschlager C, Khan F. Serum theophylline levels are increased by ciprofloxacin (Bay 9867), a new quinolone antibiotic. Chest 1985;88:32.Google Scholar
  11. 11.
    Wijnands WJA, Van Griethuysen AJA, Vree TB, Van Klingeren B, Van Herwaarden CLA. Enoxacin in lower respiratory tract infections. J Antimicrob Chemother 1986;18:719–27.PubMedGoogle Scholar
  12. 12.
    Logamann C, Ohnhaus EE. Enoxacin, a differential inhibitor of the microsomal liver enzyme system in man. Abstract 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, USA, 1987.Google Scholar
  13. 13.
    Okazaki O, Miyazaki K, Tachizawa H. Lack of effect of ofloxacin on theophylline pharmacokinetics in rats. Chemotherapy 1987;502.Google Scholar
  14. 14.
    Tang-Liu DDS, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31:358–69.PubMedGoogle Scholar
  15. 15.
    Grygiel JJ, Wing LMH, Farkas J, Birkett DJ. Effects of allopurinol on the theophylline metabolism and clearance. Clin PHarmacol Ther 1979;26:660–7.PubMedGoogle Scholar
  16. 16.
    Miners JO, Attwood J, Birkett DJ. Theobromine metabolism in man. Drug Metab Dispos 1982;10:672–5.PubMedGoogle Scholar
  17. 17.
    Betlach CJ, Tozer TN. Biodisposition of theophylline. Effect of aromatic hydrocarbon treatment in mice. Drug Metab Dispos 1980;8:271–3.PubMedGoogle Scholar
  18. 18.
    Levy G, Koysooko R. Renal clearance of theophylline in man. J Clin Pharmacol 1976;16:329–32.PubMedGoogle Scholar
  19. 19.
    Tang-Liu DDS, Williams RL, Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 1983;24:180–5.Google Scholar
  20. 20.
    Grygiel JJ, Birkett DJ. Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther 1981;30:491–6.PubMedGoogle Scholar
  21. 21.
    Rosenberry KR, Defusco CJ, Mansmann HC, McGeady SJ. Reduced theophylline half-life induced by carbamazepine therapy. J Pediatr 1983;702:472–4.Google Scholar
  22. 22.
    Manfredi RL, Vesell ES. Inhibition of theophylline metabolism by long term allopurinol administration. Clin Pharmacol Ther 1981;29:224–9.PubMedGoogle Scholar
  23. 23.
    Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med 1981;95:68–9.PubMedGoogle Scholar
  24. 24.
    Grygiel JJ, Miners JO, Drew R, Brikett DJ. Differential effects of cimetidine on theophylline metabolic pathways. Eur J Pharmacol 1984;26:335–40.Google Scholar
  25. 25.
    Jackson JE, Powell JR, Wandell M. Cimetidine decreases theophylline clearance. Am Rev Respir Dis 1981;123:615–7.PubMedGoogle Scholar
  26. 26.
    Reitberg DP, Berhard H, Schentag JJ. Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. Ann Intern Med 1981;95:582–5.PubMedGoogle Scholar
  27. 27.
    Renton KW, Gray JD, Hung OR, Depression of theophylline elimation by erythromycin. Clin Pharmacol Ther 1981;30:422–6.PubMedGoogle Scholar
  28. 28.
    Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 1983;101:821–5.PubMedGoogle Scholar
  29. 29.
    Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol 1982;23:129–34.PubMedGoogle Scholar
  30. 30.
    Wijnands WJA, Vree TB, Baars AM, Van Herwaarden CLA. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin, and pefloxacin during maintenance treatment with theophylline. Drugs 1987;34(suppl 1):159–69.PubMedGoogle Scholar
  31. 31.
    Nazario M. The hepatic and renal mechanisms of drug interactions with cimetidine. Drug Intell Clin Pharm 1986;20:342–8.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1988

Authors and Affiliations

  • W. J. A. Wijnands
    • 1
    • 2
  • T. J. Janssen
    • 3
  • P. J. M. Guelen
    • 3
  • T. B. Vree
    • 4
  • T. M. C. de Witte
    • 3
  1. 1.Department of Pulmonary DiseaseFoundation Deventer HospitalsGC Deventerthe Netherlands
  2. 2.Farma Research BVAA Ravensteinthe Netherlands
  3. 3.Department of Pulmonary DiseasesMedical Centre DekkerswaldCA Heilige, Landstichtingthe Netherlands
  4. 4.Departments of Clinical Pharmacy and AnaesthesiologySint Radboud HospitalHB Nijmegenthe Netherlands

Personalised recommendations